title: Psoriasis Area and Severity Index 50 as an endpoint in psoriasis trials: an unconvincing proposal.
authors.forename: Kenneth A
authors.initials: KA
authors.lastname: Katz
mesh_terms: D000077944:Alefacept; D002986:Clinical Trials as Topic; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care; D011565:Psoriasis / Q000188:drug therapy*; D011788:Quality of Life; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D019233:Retreatment; D012720:Severity of Illness Index
chemical_list: D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077944:Alefacept; D008727:Methotrexate